Peregrine Pharmaceuticals reported $142.44M in Debt for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Agenus AGEN:US USD 13.46M 241K
Amgen AMGN:US USD 38.94B 241M
AstraZeneca AZN:LN USD 29.3B 229M
Biocryst Pharmaceuticals BCRX:US USD 713.65M 91.47M
Bristol Myers Squibb BMY:US USD 39.1B 2.96B
Eli Lilly And LLY:US USD 15.89B 925.4M
GlaxoSmithKline GSK:LN GBP 20.99B 1.13B
Intrexon XON:US USD 82.07M 116.6M
Karyopharm Therapeutics KPTI:US USD 302.89M 201K
Mannkind MNKD:US USD 377.03M 564K
Merk MRK:US USD 30.42B 1.25B
Novartis NOVN:VX USD 28.44B 2.59B
Novavax NVAX:US USD 438.09M 10.34M
Peregrine Pharmaceuticals PPHM:US USD 142.44M 134K
Repligen RGEN:US USD 284.16M 453K
Roche Holding ROG:VX 27.75B 3.45B